Most Read Articles
KY Leung, 01 Feb 2014

Group B Streptococcus (GBS) is the commonest cause of severe early-onset neonatal infection, which is associated with a high rate of morbidity and mortality (5–10%).1-3 About half of GBS meningitis will be complicated by neurodevelopment impairment. Because the early-onset disease develops shortly and rapidly after birth, there has been little improvement in the disease treatment, and the focus thus lies in disease prevention.

Dr. Tan Toh Lick, Jemar Nicdao, 22 Jun 2017
Dr Tan Toh Lick, Consultant Obstetrician and Gynaecologist at Thomson Women’s Clinic, and Thomson Wellth Clinic Singapore, shares the complexities of diagnosing polycystic ovarian syndrome in adolescent girls
Jairia Dela Cruz, 23 Oct 2017
Evacuation proctography, magnetic resonance imaging, and transperineal and endovaginal ultrasonography demonstrate similar diagnostic test accuracy for posterior pelvic floor disorders in women with obstructed defecation syndrome, a recent study has shown.
Dr. Joseph Delano Fule Robles, 14 Oct 2016

Results of a recent clinical trial showed that treatment with niraparib, a poly ADP ribose polymerase (PARP) inhibitor,  improved progression-free survival (PFS) by more than 15 months in patients with recurrent ovarian cancer responding to platinum. 

Elagolix safe, effective for heavy menstrual bleeding

16 Oct 2017

Elagolix is safe and effective for reducing heavy menstrual bleeding in females with fibroids, a new dose-ranging, multiple-cohort study has shown.

Investigators randomized 271 females (mean age 41.8 years) to receive elagolix alone (n=160), elagolix and an add-back therapy (n=61) or placebo (n=50). The primary study outcome was the mean and percentage change in menstrual blood loss (MBL).

Females who received elagolix had significantly larger reductions in MBL from baseline to last complete treatment cycle compared with those who received placebo (p<0.01). Inclusions of add-back on therapies also reduced the MBL compared with placebo, but in magnitudes lower than those in patients who took elagolix only.

Elagolix also exerted a dose-dependent suppressive effect on heavy menstrual bleeding, with those receiving the 300 mg twice-daily doses experiencing the most suppression. Indeed, even if the total daily dose was the same, twice-daily dosing resulted in similar or greater MBL reductions.

Majority (84.4 to 96.8 percent) of females in the elagolix group had menstruation within 90 days of the last dose, resulting in a median range of time to return to menstruation of 25 to 30 days. In the placebo group, 93.3 to 100 percent of the females returned to menstruation within 90 days, and the median range of time was 11 to 19 days.

“These results provide a rationale for phase IIb and III clinical trials of longer duration to further evaluate the safety and efficacy of elagolix with add-back regimens,” said researchers.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS JPOG - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
KY Leung, 01 Feb 2014

Group B Streptococcus (GBS) is the commonest cause of severe early-onset neonatal infection, which is associated with a high rate of morbidity and mortality (5–10%).1-3 About half of GBS meningitis will be complicated by neurodevelopment impairment. Because the early-onset disease develops shortly and rapidly after birth, there has been little improvement in the disease treatment, and the focus thus lies in disease prevention.

Dr. Tan Toh Lick, Jemar Nicdao, 22 Jun 2017
Dr Tan Toh Lick, Consultant Obstetrician and Gynaecologist at Thomson Women’s Clinic, and Thomson Wellth Clinic Singapore, shares the complexities of diagnosing polycystic ovarian syndrome in adolescent girls
Jairia Dela Cruz, 23 Oct 2017
Evacuation proctography, magnetic resonance imaging, and transperineal and endovaginal ultrasonography demonstrate similar diagnostic test accuracy for posterior pelvic floor disorders in women with obstructed defecation syndrome, a recent study has shown.
Dr. Joseph Delano Fule Robles, 14 Oct 2016

Results of a recent clinical trial showed that treatment with niraparib, a poly ADP ribose polymerase (PARP) inhibitor,  improved progression-free survival (PFS) by more than 15 months in patients with recurrent ovarian cancer responding to platinum.